Skip to content

Pharmaceutical science.

ISSN 3033-3318

3 papers in the library · publishing 2025

Papers

Psychedelics in Psychiatry: New Treatment Paradigms or Addictive Treatment Strategies? A Narrative Review

Pharmaceutical science. December 9, 2025 Marco Otto Toscano, Serena Chiara Civardi, Federico Durbano

Psychedelics, studied since the 1800s, are seeing renewed scientific interest after decades of prohibition. Research points to their therapeutic potential for treatment-resistant psychiatric disorders and their usefulness for studying brain networks and consciousness. This chapter reviews the history, traditional uses, mechanisms, and clinical evidence for ayahuasca, mescaline, psilocybin, ibogaine, and LSD. It also covers regulatory and ethical issues like informed consent and cultural respect, and discusses debates on ego dissolution and 'non-subjective psychedelics.' Psychedelics are described as 'molecules of complexity' that integrate biological, psychological, and social dimensions, suggesting a paradigm shift in psychiatry. However, the data remain preliminary and not unequivocal; excessive enthusiasm could expose people to more risks than benefits if research is not rigorous.

Therapeutic Potential of Psychedelics: Mechanisms, Applications, and Challenges

Pharmaceutical science. August 27, 2025 Guilllermo Castaño-perez, Sara Isabel Castaño-ocampo

Psilocybin shows efficacy in treatment-resistant depression and cancer-associated anxiety, while MDMA combined with psychotherapy shows promise for post-traumatic stress disorder. For addictions, psilocybin is effective for alcohol use disorder and nicotine dependence, and ayahuasca shows potential for various substance use disorders. The evidence on efficacy, safety, and limitations of psychedelics like psilocybin, MDMA, LSD, and ayahuasca as monotherapy or in combination with assisted therapies is reviewed.

Psychedelics’ Intoxicating Impact and Behavioural Dynamics

Pharmaceutical science. August 19, 2025 Afshan Zeeshan Wasti

Psychedelics like psilocybin and LSD disrupt brain networks involved in self-awareness and emotion, leading to altered perception, cognition, and social behavior. These drugs amplify emotions, dissolve the ego, and increase sensory vividness—a phenomenon called tripping—which carries hazards such as anxiety and perceptual distortions, yet can also promote empathy, creativity, and psychological openness. Emerging research indicates that destabilizing the brain's default mode network may have prosocial effects but also impair judgment, affecting mental health. Unsupervised use remains dangerous due to unpredictable psychological and physiological effects.